Protocols for High-Risk Pregnancies. Группа авторов

Чтение книги онлайн.

Читать онлайн книгу Protocols for High-Risk Pregnancies - Группа авторов страница 20

Protocols for High-Risk Pregnancies - Группа авторов

Скачать книгу

       Ruta M. Nonacs

      Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA

      According to data collected in the 2015–2017 Behavioral Risk Factor Surveillance System conducted by the Centers for Disease Control and Prevention (CDC), 11.5% of pregnant women in the United States reported consuming at least one alcoholic drink during the past 30 days, and 3.9% reported binge drinking (five or more drinks during one episode). Among pregnant women who reported binge drinking, the average frequency of binge drinking was 4.5 episodes during the past 30 days. The highest prevalence of alcohol use during pregnancy was observed in older (ages 35–44 years), college educated, and unmarried women.

      According to the same surveillance, the prevalence of any alcohol use was 53.6% among nonpregnant reproductive age women, indicating that pregnancy may be a time of increased motivation to decrease or stop drinking. Even among women with heavy alcohol use or patterns of use consistent with alcohol use disorder, 70–90% abstain from alcohol during pregnancy. Although many women achieve abstinence during pregnancy, studies have noted high rates of relapse during the postpartum period.

      Alcohol exposure during pregnancy also increases the risk of low birthweight and extreme preterm birth (<32 weeks’ gestation), factors which may contribute to higher rates of neonatal morbidity and mortality and may have long‐term neurodevelopmental consequences.

      Most studies have focused on the negative effects of alcohol on fetal development. Alcohol is a known teratogen and exposure early in pregnancy, during the period of organogenesis, has been associated with growth restriction and a constellation of physical abnormalities, including dysmorphic facial features, microcephaly, cardiac defects, and eye and ear abnormalities. Exposure to alcohol at any point during the pregnancy can compromise development of the fetal brain. Prenatal alcohol exposure is one of the leading causes of mental retardation and may result in long‐term deficits in cognitive, behavioral, and emotional functioning.

      Fetal alcohol spectrum disorders (FASD) encompass several diagnostic subtypes. Children with fetal alcohol syndrome (FAS) are the most severely affected and present with characteristic facial features (e.g., thin upper lip, small, wide‐set eyes, upturned nose), microcephaly, small stature, and cognitive deficits, including developmental delays and lower IQ, as well as emotional and behavioral problems. Children with alcohol‐related neurodevelopmental disorder (ARND) lack the characteristic facial defects and growth retardation seen in children with FAS but have alcohol‐induced mental impairment.

      The effects of alcohol exposure on the developing fetus are variable. While any amount of alcohol consumption may have adverse effects, binge drinking is especially concerning as it has been associated with higher risk of FASD. Children born to women of lower socioeconomic status appear to be more susceptible to the effects of alcohol in utero, a finding which suggests that other factors, including nutritional status and environmental exposures, may contribute to the pathophysiology of FASD. Currently, there is no known amount of alcohol consumption during pregnancy which is considered to be safe.

      Prevalence estimates of FAS have varied widely from 0.5 to 3 per 1000 live births; however, studies using in‐person assessments of school‐aged children report higher estimates of FAS: 6–9 per 1000 children. Few estimates for the full range of FASDs are available; the most current estimate of the prevalence of FASD among US children is approximately 1%.

      It has been demonstrated that alcohol inhibits the release of oxytocin, the hormone which stimulates milk ejection, an effect which decreases the amount of milk available to the nursing infant. Higher amounts of alcohol intake appear to have a greater effect; however, one study noted that drinking as little as 0.3 g alcohol per kg (a little more than a 12‐ounce beer or mixed drink) may reduce milk production by about 10%. Other studies have observed that the infants of mothers who consume alcohol tend to take in less breast milk per feeding and may also have disrupted sleep patterns.

      The long‐term effects of alcohol delivered to infants via breast milk have not been well studied. In a study of 400 infants born to women in a health maintenance organization, motor development, as measured by the Psychomotor Development Index (PDI), was significantly lower in infants exposed regularly to alcohol in breast milk (even after controlling for prenatal alcohol exposure), with an inverse dose–response relationship noted between frequency of maternal alcohol consumption and scores on the PDI. In a similar study from the same group, however, there was no association between alcohol exposure and scores on the Griffiths Developmental Scales in 18‐month‐old children.

      Breastfeeding while consuming alcohol may carry some neurodevelopmental risk for the infant; however, of greater concern is the impact alcohol may have on childcare and safety. Parental use of alcohol is considered a risk factor for sudden infant death syndrome and other infant sleep‐related deaths. Maternal alcohol use disorder (AUD) is associated with poor parenting skills, inadequate supervision, family disruption and conflict, family mobility, and increased risk for child abuse and neglect.

      All women seeking obstetric care should be screened for alcohol use within the first trimester of pregnancy and again during the postpartum period; however, screening for alcohol use in an obstetric setting can be more complicated. Many women fear that disclosure of their alcohol use may have negative consequences, such as criminal or civil penalties or the loss of custody of their children. Therefore, it is crucial that, when screening for substance use, clinicians must assure their patients that the information disclosed is privileged and confidential.

      Many

Скачать книгу